Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
06 sept. 2023 08h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at Upcoming Investor Conferences
30 août 2023 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
24 août 2023 09h00 HE
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
10 août 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed...
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
01 août 2023 22h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
31 juil. 2023 16h29 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
25 juil. 2023 07h00 HE
|
Tarsus Pharmaceuticals, Inc
XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the...
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
12 juin 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at the Jefferies Global Healthcare Conference
05 juin 2023 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
09 mai 2023 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a...